Does the BAFF dysregulation play a major role in the pathogenesis of systemic lupus erythematosus?

Journal of Autoimmunity

Volumn 30, Issue 1-2, 2008, Pages 63-67

  Binard, Aymeric ^a   Le Pottier, Laëtitia ^a   Saraux, Alain ^a   Devauchelle Pensec, Valérie ^a   Pers, Jacques Olivier ^a   Youinou, Pierre ^a  

^a BREST UNIVERSITY HOSPITAL   (France)

Author keywords

B lymphocyte; BAFF; Systemic lupus erythematosus

Indexed keywords

B CELL ACTIVATING FACTOR; BELIMUMAB; RITUXIMAB; TUMOR NECROSIS FACTOR;

B LYMPHOCYTE; CELL ACTIVITY; CELL SURVIVAL; CLINICAL TRIAL; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION;

ANIMALS; AUTOIMMUNITY; B-CELL ACTIVATING FACTOR; B-CELL ACTIVATION FACTOR RECEPTOR; B-LYMPHOCYTES; HUMANS; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, TRANSGENIC;

EID: 38049065080     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2007.11.001     Document Type: Review

References (57)

1. Lipsky P.E. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2 (2001) 764-766
2. Jacobi A.M., and Diamond B. Balancing diversity and tolerance: lessons from patients with systemic lupus erythematosus. J Exp Med 202 (2005) 341-344
3. Anolik J.H., Campbell D., Felgar R.E., Young F., Sanz I., Rosenblatt J., et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48 (2003) 455-459
4. Edwards J.C., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Emery P., Close D.R., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350 (2004) 2572-2581
5. Pers J.O., Devauchelle V., Daridon C., Bendaoud B., Le Berre R., Bordron A., et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Arthritis Rheum 56 (2007) 1464-1477
6. Wardemann H., Yurasov S., Schaefer A., Young J.W., Meffre E., and Nussenzweig M.C. Predominant autoantibody production by early human B cell precursors. Science 301 (2003) 1374-1377
7. Schneider P., MacKay F., Steiner V., Hofmann K., Bodmer J.L., Holler N., et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189 (1999) 1747-1756
8. Batten M., Groom J., Cachero T.G., Qian F., Schneider P., Tschopp J., et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 192 (2000) 1453-1466
9. Schiemann B., Gommerman J.L., Vora K., Cachero T.G., Shulga-Morskaya S., Dobles M., et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 293 (2001) 2111-2114
10. Thien M., Phan T.G., Gardam S., Amesbury M., Basten A., Mackay F., et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20 (2004) 785-798
11. Mackay F., Woodcock S.A., Lawton P., Ambrose C., Baetscher M., Schneider P., et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190 (1999) 1697-1710
12. Groom J., Kalled S.L., Cutler A.H., Olson C., Woodcock S.A., Schneider P., et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 109 (2002) 59-68
13. Karpusas M., Cachero T.G., Qian F., Boriack-Sjodin A., Mullen C., Strauch K., et al. Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes. J Mol Biol 315 (2002) 1145-1154
14. Oren D.A., Li Y., Volovik Y., Morris T.S., Dharia C., Das K., et al. Structural basis of BLyS receptor recognition. Nat Struct Biol 9 (2002) 288-292
15. Liu Y., Xu L., Opalka N., Kappler J., Shu H.B., and Zhang G. Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands. Cell 108 (2002) 383-394
16. Roschke V., Sosnovtseva S., Ward C.D., Hong J.S., Smith R., Albert V., et al. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 169 (2002) 4314-4321
17. Daridon C, Youinou P, Pers JO. BAFF, APRIL, TWE-PRIL: who's who? Autoimmun Rev 2007, in press.
18. Gavin A.L., Aït-Azzouzene D., Ware C.F., and Nemazee D. DeltaBAFF, an alternate splice isoform that regulates receptor binding and biopresentation of the B cell survival cytokine, BAFF. J Biol Chem 278 (2003) 38220-38228
19. Gavin A.L., Duong B., Skog P., Aït-Azzouzene D., Greaves D.R., Scott M.L., et al. deltaBAFF, a splice isoform of BAFF, opposes full-length BAFF activity in vivo in transgenic mouse models. J Immunol 175 (2005) 319-328
20. Daridon C., Devauchelle V., Hutin P., Le Berre R., Martins-Carvalho C., Bendaoud B., et al. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum 56 (2007) 1134-1144
21. Cancro M.P. The BLyS family of ligands and receptors: an archetype for niche-specific homeostatic regulation. Immunol Rev 202 (2004) 237-249
22. Yu G., Boone T., Delaney J., Hawkins N., Kelley M., Ramakrishnan M., et al. APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nat Immunol 1 (2000) 252-256
23. Ng L.G., Sutherland A.P., Newton R., Qian F., Cachero T.G., Scott M.L., et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol 173 (2004) 807-817
24. Ingold K., Zumsteg A., Tardivel A., Huard B., Steiner Q.G., Cachero T.G., et al. Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 201 (2005) 1375-1383
25. Claudio E., Brown K., Park S., Wang H., and Siebenlist U. BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat Immunol 3 (2002) 958-965
26. Kayagaki N., Yan M., Seshasayee D., Wang H., Lee W., French D.M., et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity 17 (2002) 515-524
27. Shulga-Morskaya S., Dobles M., Walsh M.E., Ng L.G., MacKay F., Rao S.P., et al. B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J Immunol 173 (2004) 2331-2341
28. Yan M., Wang H., Chan B., Roose-Girma M., Erickson S., Baker T., et al. Activation and accumulation of B cells in TACI-deficient mice. Nat Immunol 2 (2001) 638-643
29. Cyster J.G., Hartley S.B., and Goodnow C.C. Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire. Nature 371 (1994) 389-395
30. Zhang J., Roschke V., Baker K.P., Wang Z., Alarcon G.S., Fessler B.J., et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 166 (2001) 6-10
31. Pers J.O., Daridon C., Devauchelle V., Jousse S., Saraux A., Jamin C., et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 1050 (2005) 34-39
32. Stohl W., Metyas S., Tan S.M., Cheema G.S., Oamar B., Xu D., et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 48 (2003) 3475-3486
33. Ju S., Zhang D., Wang Y., Ni H., Kong X., and Zhong R. Correlation of the expression levels of BLyS and its receptors mRNA in patients with systemic lupus erythematosus. Clin Biochem 39 (2006) 1131-1137
34. Carter R.H., Zhao H., Liu X., Pelletier M., Chatham W., Kimberly R., et al. Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus. Arthritis Rheum 52 (2005) 3943-3954
35. Groom J.R., Fletcher C.A., Walters S.N., Grey S.T., Watt S.V., Sweet M.J., et al. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med 204 (2007) 1959-1971
36. Shoenfeld Y., Toubi E., and Hiepe F. Eighth international workshop on autoantibodies and autoimmunity Berlin, Germany, 10-13 September 2003. Autoimmun Rev 3 (2004) 77-84
37. Vallerskog T., Heimbürger M., Gunnarsson I., Zhou W., Wahren-Herlenius M., Trollmo C., et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 8 (2006) R167
38. Anolik J.H., Barnard J., Owen T., Zheng B., Kemshetti S., Looney R.J., et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 56 (2007) 3044-3056
39. Abraham M., Karni A., Dembinsky A., Miller A., Gandhi R., Anderson D., et al. In vitro induction of regulatory T cells by anti-CD3 antibody in humans. J Autoimmun 30 (2008) 21-28
40. Andreoli L., Pregnolato F., Burlingame R.W., Allegri F., Rizzini S., Fanelli V., et al. Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity?. J Autoimmun 30 (2008) 51-57
41. Fleming S.D., and Tsokos G.C. Complement, natural antibodies, autoantibodies and tissue injury. Autoimmun Rev 5 (2006) 89-92
42. Goules A., Tzioufas A.G., Manousakis M.N., Kirou K.A., Crow M.K., and Routsias J.G. Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. J Autoimmun 26 (2006) 165-171
43. Jacobson E., Huber A., and Tomer Y. The HLA gene complex in thyroid autoimmunity: from epidemiology to etiology. J Autoimmun 30 (2008) 58-62
44. Kallenberg C. Pathogenesis of PR3-ANCA associated vasculitis. J Autoimmun 30 (2008) 29-36
45. Knight A.K., and Cunningham-Rundles C. Inflammatory and autoimmune complications of common variable immune deficiency. Autoimmun Rev 5 (2006) 156-159
46. Mackay I., Leskovek N., and Rose N. Cell damage and autoimmunity: a critical appraisal. J Autoimmun 30 (2008) 5-11
47. Milner J., Ward J., Keane-Myers A., Min B., and Paul W.E. Repertoire-dependent immunopathology. J Autoimmun 29 (2007) 257-261
48. Nakanishi Y., Tsuneyama K., Fujimoto M., Salunga T.L., Nomoto K., An J.-L., et al. Monosodium glutamate (MSG): a villain and promoter of liver inflammation and dysplasia. J Autoimmun 30 (2008) 42-50
49. Poletaev A., Stepanyuk V., and Gershwin M. Integrating immunity: the immunculus and self reactivity. J Autoimmun 30 (2008) 68-73
50. Praprotnik S., Sodin-Semrl S., Tomsic M., and Shoenfeld Y. The curiously suspicious: infectious disease may ameliorate an ongoing autoimmune destruction in systemic lupus erythematosus patients. J Autoimmun 30 (2008) 37-41
51. Prelog M. Aging of the immune system: a risk factor for autoimmunity?. Autoimmun Rev 5 (2006) 136-139
52. Recalcati S., Invernizzi P., Arosio P., and Cairo G. New functions for an iron storage protein: the role of ferritin in immunity and autoimmunity. J Autoimmun 30 (2008) 84-89
53. Rodriguez-Reyna T.S., and Alarcon-Segovia D. The different faces of shared autoimmunity. Autoimmun Rev 5 (2006) 86-88
54. Rowley B., Tang L., Shinton S., Hayakawa K., and Hardy R.R. Autoreactive B-1 B cells: constraints on natural autoantibody B cell antigen receptors. J Autoimmun 29 (2007) 236-245
55. Sanchez-Pernaute O., Ospelt C., Neidhart M., and Gay S. Epigenetic clues to rheumatoid arthritis. J Autoimmun 30 (2008) 12-20
56. Shoenfeld Y., and Gershwin M. Autoimmunity: from the mosaic to the kaleidoscope. J Autoimmun 30 (2008) 1-4
57. Somers V., Govarts C., Hellings N., Hupperts R., and Stinissen P. Profiling the autoantibody repertoire by serological antigen selection. J Autoimmun 25 (2005) 223-228